IkedaKSanayamaYMakitaS, et al.
Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol2013;
2013: 697525–697512.
2.
FurieRDooleyMAWofsyD, et al.
OP0253 a phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis. Ann Rheum Dis2018.
77: 176–177.
3.
Pimentel-QuirozVRUgarte-GilMFAlarconGS.Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs2016;
25: 493–499.
4.
Serrano-BenaventeBBelloNNieto-GonzálezJC, et al.
AB0406 clinical experience from abatacept use in systemic lupus erythematosus: effectiveness and safety. Ann Rheum Dis2016;
75: 1045–1045.
5.
TaraziMAiempanakitKWerthVP.Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. JAAD Case Rep2018;
4: 698–700.
6.
AsamiYIshiguroHUedaA and Nakajima H.
First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis. Clin Exp Rheumatol2016;
34: 1122.
